Fighting Osteoporosis With Risedronate Co-Therapy During Incretin (FORTIFY)
Bisphosphonate Co-Therapy to Preserve Musculoskeletal Health in Older Adults Using Tirzepatide
Tirzepatide produces rapid, clinically meaningful weight loss. In older adults, however, substantial weight reduction may accelerate loss of bone and muscle, increase frailty risk, and compound age-related skeletal vulnerability. The purpose of this study is to find out if taking risedronate along with tirzepatide preserves musculoskeletal health during tirzepatide-associated weight loss.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Tirzepatide produces rapid, clinically meaningful weight loss. Weight loss of this magnitude is accompanied by increased bone turnover, hip bone loss, and loss of fat-free mass. Risedronate is a bisphosphonate therapy that inhibits osteoclast-mediated bone resorption and has an established monthly oral regimen. Pilot bariatric-surgery data from the investigative team support feasibility [1], attenuation of bone loss and resorption [2], and a signal for preservation of appendicular lean mass [3]. This single-center, 12-month, randomized, double-blind, placebo-controlled, parallel-group phase 3 clinical trial evaluates the premise that risedronate will blunt the skeletal consequences of tirzepatide-associated weight loss and may secondarily preserve muscle through bone-muscle signaling pathways.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Kim Kennedy
- Phone Number: 336.713.8567
- Email: Kimberly.Kennedy@Advocatehealth.org
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Atrium Health Wake Forest Baptist
-
Contact:
- Kim Kennedy
- Phone Number: 336-713-8567
- Email: Kimberly.Kennedy@Advocatehealth.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI≥30 or 27.0-29.9 kg/m2 plus one weight related co-morbidity
- Weight stability (within 5% in past 3 months)
- Community dwelling
- English speaking
- Able to attend regular in person appointments, willingness to take tirzepatide and risedronate medication, and willing to provide informed consent
Exclusion Criteria:
- Weight >450 lbs (DXA limit)
- Disordered alcohol or substance use
- Eating disorder in past 5 years
- >1 fall (injurious or non-injurious) in past year or prior fragility fracture
- Osteoporosis (self-report, medication use, or T-score ≤ -2.5 on hip or spine DXA scan)
- Use of oral corticosteroids (>5 d/month in past 3 months), use of incretin analog (GLP1Ra or dual agonist) in past 24 months, use of any AOM or prescription osteoporosis medication in last 12 months, history of intolerance or adverse reaction to GLP1Ra (other incretin analog) or bisphosphonate, concomitant use of insulin secretagogues or insulin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tirzepatide Plus Risedronate
|
Tirzepatide 2.5 mg weekly for 4 weeks, then 5 mg, 7.5 mg, and 10 mg at 4-week intervals as tolerated; continue 10 mg weekly through month 12. Risedronate 150 mg orally once monthly for 12 doses |
|
Active Comparator: Tirzepatide Plus Placebo
|
Tirzepatide 2.5 mg weekly for 4 weeks, then 5 mg, 7.5 mg, and 10 mg at 4-week intervals as tolerated; continue 10 mg weekly through month 12. risedronate matching placebo orally once monthly for 12 doses |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Hip Bone Mineral Density
Time Frame: from baseline to month 12
|
change in total hip areal bone mineral density by DXA |
from baseline to month 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Appendicular Lean Mass
Time Frame: Month 6, Month 12
|
appendicular lean mass by DXA |
Month 6, Month 12
|
|
Hip Bone Strength
Time Frame: Month 6, Month 12
|
hip bone strength by QCT-derived finite element analysis |
Month 6, Month 12
|
|
Distal Tibia Trabecular Number
Time Frame: Month 6, Month 12
|
distal tibia trabecular number by HR-pQCT |
Month 6, Month 12
|
|
Gait Speed
Time Frame: Month 6, Month 12
|
fast-paced gait speed from the 400-m walk test |
Month 6, Month 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ashley Weaver, PhD, Atrium Health Wake Forest Baptist
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Overweight
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Bone Diseases, Metabolic
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Pyridines
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Organophosphorus Compounds
- Glucagon-Like Peptide-1 Receptor
- Glucagon-Like Peptide Receptors
- Receptors, G-Protein-Coupled
- Receptors, Cell Surface
- Membrane Proteins
- Receptors, Gastrointestinal Hormone
- Receptors, Peptide
- Organophosphonates
- Diphosphonates
- Risedronic Acid
- Tirzepatide
Other Study ID Numbers
Other Study ID Numbers
- IRB00158768
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.